RTTNews | Oct 12, 2021 11:53AM EDT

11:52 Tuesday, October 12, 2021 (RTTNews.com) - Shares of CureVac N.V. (CVAC) slipped nearly 7% on Tuesday morning after the company withdraws its first mRNA-based Covid vaccine from approval process.

CVAC is currently trading at $40.27, down $2.90 or 6.73%, on the Nasdaq.

The company said it decided to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency due to potential overlap with approval timelines for a second-generation candidate. The company will focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK.

Read the original article on RTTNews ( https://www.rttnews.com/3232137/curevac-stock-down-7-after-it-withdraws-covid-19-vaccine-candidate-from-ema-approval-process.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved